Epidemiology of Childhood Asthma in the UK
Imène Gouia,Florence Joulain,Yi Zhang,Christopher Morgan,Asif Khan
DOI: https://doi.org/10.2147/jaa.s452741
2024-11-27
Journal of Asthma and Allergy
Abstract:Imène Gouia, 1 Florence Joulain, 1 Yi Zhang, 2 Christopher Ll Morgan, 3 Asif H Khan 4 1 Health Economics and Value Assessment, Sanofi, Gentilly, France; 2 Medical Affairs, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA; 3 Epidemiology, Pharmatelligence Ltd, Cardiff, UK; 4 Global Medical, Sanofi, Bridgewater, NJ, USA Correspondence: Imène Gouia, Sanofi, 82 Avenue Raspail, Gentilly, Cedex, 94255, France, Tel +33786980603, Email Purpose: Global prevalence of pediatric asthma and associated morbidity and mortality has continuously increased. Asthma is the most common chronic illness in children in the UK; however, recent epidemiology data are lacking. This analysis describes the overall prevalence and burden of illness of asthma in children. Methods: This was a retrospective, longitudinal, database analysis using the Clinical Practice Research Datalink database. Primary care records of 19,330 patients (6– 11 years) between January 1 and December 31, 2017, were analyzed. Asthma prevalence was assessed by severity (as described by Global Initiative for Asthma 2017 guidelines), and symptoms, comorbidities, and treatments were compared between asthma patients and matched non-asthmatic controls. Results are presented descriptively; logistic regression analyses were performed for asthma symptoms. Results: The estimated prevalence of pediatric asthma was 6.5% (95% CI: 6.4– 6.5) in the UK (mild: 74.2%; moderate: 15.0%; severe: 10.8%). All patients with moderate or severe asthma and 72.5% of patients with mild asthma were prescribed drug therapy. Most patients with moderate or severe asthma were prescribed a short-acting β 2-agonist (94.9% and 96.0%, respectively), compared with 69.2% of mild asthma patients. Daytime symptoms were reported by 78.1% in those with severe asthma; 34.9% reported night-time symptoms and 30.8% reported an impact on usual activities. Asthma patients had a higher baseline prevalence of comorbidities compared with non-asthmatic controls, notably atopic dermatitis (47.8% in severe asthma versus 20.8% in controls) and allergic rhinitis (13.3% in severe asthma versus 2.0% in controls). Conclusion: This analysis confirmed that asthma remains a common morbidity among children in the UK. Increasing asthma severity was associated with worsening symptoms, and asthma patients had significantly more comorbidities compared with non-asthmatic controls. Keywords: asthma, pediatric, epidemiology, United Kingdom The global prevalence of pediatric asthma and associated morbidity and mortality has continuously increased over the past 40 years. 1 However, the prevalence of childhood asthma varies considerably by geographic region; 1,2 the highest rates are reported in Southeast Asia, North America, and Latin America. 1 In the UK, asthma is the most common chronic illness in children, but more recent epidemiology data are needed to characterize asthma in children. 3 Pediatric asthma has a significant economic impact on the National Healthcare System: there were over 6000 inpatient admissions in England in 2020/2021 for asthma in children aged ≤9 years, 4 and over 1 million children received treatment for asthma across the UK. 5 Asthma symptoms differ between children, because risk factors and clinical burden depend on specific asthmatic phenotypes; atopic asthma and episodic viral wheeze are most commonly observed in children. 6 Disease management is specific to each phenotype and consists of drug therapy (which also includes rescue therapy, such as short-acting β2-agonists [SABAs]), additional maintenance medication, and avoiding asthma triggers. 7,8 Additionally, diagnosing and managing asthma in children is more difficult than in adults. 9,10 However, reviews in low income populations have shown indications of under-diagnosis or misdiagnosis of asthma across age groups, while studies in high income populations suggest over-diagnosis of asthma. 11–14 A potential reason for this is the lack of a gold standard for the diagnosis of asthma. 15 This study aimed to address the lack of recent data on epidemiology and characteristics of asthma in children in order to better understand the clinical burden of this heterogenous disease. 16 The primary objective of this study was to estimate the overall prevalence of asthma in children aged 6 to 11 years in the UK and to characterize the burden of illness (symptoms, comorbidities, and treatment patterns) in children with asthma using data from a real-world UK database, the Clinical Practice Research Datalink (CPRD). Prevalence and treatment patterns were further stratified by le -Abstract Truncated-
immunology,allergy,respiratory system